Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Assets (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Assets for 13 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 179.34% year-over-year to $21.1 million, compared with a TTM value of $21.1 million through Dec 2025, up 179.34%, and an annual FY2025 reading of $21.1 million, up 179.34% over the prior year.
  • Assets was $21.1 million for Q4 2025 at Abvc Biopharma, down from $21.2 million in the prior quarter.
  • Across five years, Assets topped out at $21.2 million in Q3 2025 and bottomed at $6.7 million in Q4 2023.
  • Average Assets over 5 years is $12.0 million, with a median of $10.6 million recorded in 2021.
  • The sharpest move saw Assets plummeted 53.12% in 2024, then skyrocketed 179.34% in 2025.
  • Year by year, Assets stood at $13.7 million in 2021, then plummeted by 30.07% to $9.6 million in 2022, then fell by 29.97% to $6.7 million in 2023, then increased by 12.4% to $7.5 million in 2024, then soared by 179.34% to $21.1 million in 2025.
  • Business Quant data shows Assets for ABVC at $21.1 million in Q4 2025, $21.2 million in Q3 2025, and $16.2 million in Q2 2025.